GILD HIV and hepatitis treatments

What happened: Cantor Fitzgerald reiterated an 'Overweight' rating and a $155 price target for Gilead Sciences (GILD) on June 9, citing positive HIV trial results. Gilead's stock is seen as a top 'set-it-and-forget-it' investment. Meanwhile, Gilead continues to expand its portfolio with new oncology and inflammation therapies, and its stock offers an attractive dividend yield.

Market impact: The positive trial results and analyst endorsement have driven GILD's stock price up, benefiting investors who have held the stock. The success of Gilead's new therapies and acquisitions could reshape the market's perception of the company, shifting focus from its HIV portfolio to its broader pipeline.

What to watch next: Upcoming catalysts include the release of detailed HIV trial data, expected in Q3 2023, and the U.S. FDA's decision on Gilead's filgotinib for rheumatoid arthritis, anticipated in Q4 2023. Additionally, investors will monitor Gilead's earnings reports for updates on its expanding pipeline and financial performance.